CervoMed is trading 5.29% down at $2.15, in a decline consistent with broader market pressure; no company-specific cause has been identified. - Hotter-than-expected September inflation lifted rate-hike concerns and pushed U.S. stocks lower, though this does not establish a company-specific cause for the move. - No new company-specific announcement explaining the October 14 move was identified. The latest company update was October 12, when CervoMed reported initial Phase 2a biomarker results.